

SUPPORT FOR THE AMENDMENTS

The amendments to Claims 7 and 21 are supported by the specification at pages 6-17.

No new matter is believed to have been added to this application by these amendments.

REMARKS


Claims 7-42 remain pending.

Claims 7 and 21 have been amended so that the clean copy and the marked-up copies are the same.

Applicants submit that the present application is in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

James J. Kelly, Ph.D.
Registration No. 41,504



22850

ATTORNEY DOCKET NO.: 1587-0024-0
SERIAL NO.: 08/893,759

MARKED-UP COPY

Serial No.: 08/893,759
Amendment Filed On: Herewith

IN THE CLAIMS

--7. (Amended Four Times) An agglutination immunoassay for detecting an antigen in a sample, comprising:

(a) sequentially contacting the sample with

(i) a first antibody which is capable of specifically binding to a first binding site on the antigen, wherein the first antibody is immobilized on an insoluble carrier, and then

(ii) a second antibody which is capable of specifically binding to a second binding site on the antigen, wherein the second antibody is free,

thereby forming, when the antigen is present in the sample, an agglutinate comprising the first antibody, the antigen, and the second antibody; followed by

(b) optically measuring the amount of the agglutinate formed in (a); followed by

(c) correlating the amount of agglutinate formed with the amount of the antigen in the sample,

wherein the antigen is apoprotein B, HbA₁C, serum amyloid A protein, or thrombin-antithrombin III complex

[wherein one of the antibodies has high specificity for the antigen while the other antibody does not have strict specificity for the antigen].

21. (Amended Four Times) An agglutination immunoassay for detecting an antigen in a sample, comprising:

(a) sequentially contacting the sample with

(i) a first antibody which is capable of specifically binding to a first binding site on the antigen, wherein the first antibody is free, and then

(ii) a second antibody which is capable of specifically binding to a second binding site on the antigen, wherein the second antibody is immobilized on an insoluble carrier,

thereby forming, when the antigen is present in the sample, an agglutinate comprising the first antibody, the antigen, and the second antibody; followed by

(b) optically measuring the amount of the agglutinate formed in (a); followed by

(c) correlating the amount of agglutinate formed with the amount of the antigen in the sample,


wherein the antigen is apoprotein B, HbA₁C, serum amyloid A protein, or thrombin-antithrombin III complex

[wherein one of the antibodies has high specificity for the antigen while the other antibody does not have strict specificity for the antigen].



Docket No.: 1587-0024-0

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231



ATTORNEYS AT LAW

RE: Application Serial No.: 08/893,759
Applicants: Kazunori SAITOH et al.
Filing Date: July 11, 1997
For: IMMUNOASSAY
Group Art Unit: 1641
Examiner: Chin

RECEIVED
APR 18 2003
TECH CENTER 1600/2900

SIR:

Attached hereto for filing are the following papers:

AMENDMENT AND REQUEST FOR RECONSIDERATION (WITH MARKED-UP COPY)

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon
Registration No. 24,618

James J. Kelly, Ph.D.
Registration No. 41,504



22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)